Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)

Published:2018-03-26 Issue:11 Volume:124 Page:2407-2414
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hirsch Fred R.¹,Sequist Lecia V.²,Gore Ira³,Mooradian Meghan²^ORCID,Simon George⁴,Croft Elisabeth F.⁵,DeVincenzo Diana⁶,Munley Jiefen⁶,Stein Dara⁷,Freivogel Klaus⁸,Sifakis Frangiscos⁵,Bunn Paul A.¹

Affiliation:

1. University of Colorado Cancer Center; Denver Colorado

2. Massachusetts General Hospital Cancer Center; Boston Massachusetts

3. Alabama Oncology-St Vincent's Birmingham; Birmingham Alabama

4. The University of Texas MD Anderson Cancer Center; Houston Texas

5. AstraZeneca Pharmaceuticals, LP; Gaithersburg Maryland

6. AstraZeneca Pharmaceuticals, LP; Wilmington Delaware

7. United BioSource Corporation; Montreal Quebec Canada

8. United BioSource Corporation; Munich Germany

Funder

AstraZeneca

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference29 articles.

1. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial;Ranson;J Clin Oncol.,2002

2. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies;Hidalgo;J Clin Oncol.,2001

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med.,2004

4. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci U S A.,2004

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Factors and Preventive Measures for Lung Cancer in the European Union;Epidemiologia;2024-08-27

2. Patient Age andEGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study;Anticancer Research;2024-03-27

3. Gefitinib triumphs: Long-term advantages over chemotherapy in the treatment of EGFR mutant lung cancer;Cancer Research, Statistics, and Treatment;2024-01

4. Inhibitory effect and mechanism of hirsuteine on NCI‑H1299 lung cancer cell lines;Oncology Letters;2023-04-05

5. Comparing Gefitinib and Traditional Chemotherapy for Better Survival in Patients With Non-Small Cell Lung Cancer: A Systematic Review;Cureus;2023-01-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3